Journal article · 2026 · Open access

Evaluating Patient Preferences for Clinical Trial Endpoints in Early-Stage Cancer: A Discrete Choice Experiment in Canada

Alexis T. Mickle, Frances Simbulan, Bianca Li, Kristoph Klein-Panneton, Conor L. Morrison, Sarah Walker, Karissa M. Johnston, Stephanie Snow

Current Oncology, 33(6), 308 · Published 26 May 2026 · DOI 10.3390/curroncol33060308

Open full textCite this paper

In brief

“Evaluating Patient Preferences for Clinical Trial Endpoints in Early-Stage Cancer: A Discrete Choice Experiment in Canada” is a 2026 journal article by Alexis T. Mickle and 7 co-authors, published in Current Oncology. OpenAlex counts 0 citations as of 22 November 2026. It is open access under a CC BY licence: the full text is free to read at Current Oncology.

Citations
0
References
38
Authors
8

Abstract

To quantify preferences and trade-offs for non-overall survival (OS) endpoints among Canadian adults treated for early-stage cancers, participants completed ten choice sets in a discrete choice experiment. Standard-of-care (SoC) was compared to new treatment profiles defined by five attributes: five-year OS, two-year disease advancement, pathological complete response (pCR), and short- and long-term side effects. SoC attribute levels remained constant across respondents, except OS, which varied. For the new treatment, all attributes except OS (fixed as unknown) varied. Data were analyzed using logistic regression and presented as odds ratios (ORs) with 95% confidence intervals (CIs). Among 103 adults treated for early-stage gastrointestinal (n = 40), breast (n = 32), or lung (n = 31) cancer, median age was 59 (Q1, Q3: 43, 75) years; 46.6% were female. Each 25% decrease in SoC OS was associated with higher odds of choosing the new treatment (OR 3.49; 95% CI 2.82–4.31; p < 0.01). Reductions in disease advancement (OR 1.55; 1.26–1.91; p < 0.01) and mild or no short-term side effects versus severe (OR 6.67; 4.35–10.00) significantly increased selection odds; long-term side effects and pCR showed modest, non-significant influence. When OS data were available for SoC, OS strongly influenced decisions; without OS data for new treatments, participants prioritized disease control and short-term tolerability.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Mickle, A. T., Simbulan, F., Li, B., Klein-Panneton, K., Morrison, C. L., Walker, S., Johnston, K. M., & Snow, S. (2026). Evaluating Patient Preferences for Clinical Trial Endpoints in Early-Stage Cancer: A Discrete Choice Experiment in Canada. Current Oncology, 33(6), 308. https://doi.org/10.3390/curroncol33060308

MLA 9

Mickle, Alexis T., et al. “Evaluating Patient Preferences for Clinical Trial Endpoints in Early-Stage Cancer: A Discrete Choice Experiment in Canada.” Current Oncology, vol. 33, no. 6, 2026, p. 308. https://doi.org/10.3390/curroncol33060308.

Chicago

Mickle, Alexis T., Frances Simbulan, Bianca Li, Kristoph Klein-Panneton, Conor L. Morrison, Sarah Walker, Karissa M. Johnston, and Stephanie Snow. 2026. “Evaluating Patient Preferences for Clinical Trial Endpoints in Early-Stage Cancer: A Discrete Choice Experiment in Canada.” Current Oncology 33 (6): 308. https://doi.org/10.3390/curroncol33060308.

Harvard

Mickle, A. T. et al. (2026) ‘Evaluating Patient Preferences for Clinical Trial Endpoints in Early-Stage Cancer: A Discrete Choice Experiment in Canada’, Current Oncology, 33(6), p. 308. doi:10.3390/curroncol33060308.

IEEE

A. T. Mickle et al., “Evaluating Patient Preferences for Clinical Trial Endpoints in Early-Stage Cancer: A Discrete Choice Experiment in Canada,” Current Oncology, vol. 33, no. 6, p. 308, 2026, doi: 10.3390/curroncol33060308.

BibTeX

@article{mickle2026evaluating,
  title     = {{Evaluating Patient Preferences for Clinical Trial Endpoints in Early-Stage Cancer: A Discrete Choice Experiment in Canada}},
  author    = {Mickle, Alexis T. and Simbulan, Frances and Li, Bianca and Klein-Panneton, Kristoph and Morrison, Conor L. and Walker, Sarah and Johnston, Karissa M. and Snow, Stephanie},
  journal   = {Current Oncology},
  year      = {2026},
  volume    = {33},
  number    = {6},
  pages     = {308},
  doi       = {10.3390/curroncol33060308},
  url       = {https://doi.org/10.3390/curroncol33060308}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Environmental Valuation

  • patient preferences
  • clinical trial endpoints
  • early-stage cancer
  • overall survival
  • pathological complete response
  • treatment side effects
  • disease progression
  • gastrointestinal cancer

Work with this paper

Most-cited papers in Economics, Econometrics and Finance

All highly cited Economics, Econometrics and Finance papers

Questions about this paper

How do I cite this paper in APA style?

Mickle, A. T., Simbulan, F., Li, B., Klein-Panneton, K., Morrison, C. L., Walker, S., Johnston, K. M., & Snow, S. (2026). Evaluating Patient Preferences for Clinical Trial Endpoints in Early-Stage Cancer: A Discrete Choice Experiment in Canada. Current Oncology, 33(6), 308. https://doi.org/10.3390/curroncol33060308

How many times has this paper been cited?

0 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Current Oncology: sign in and open the full text from this page.

Who wrote this paper?

Alexis T. Mickle, Frances Simbulan, Bianca Li, Kristoph Klein-Panneton, Conor L. Morrison, Sarah Walker, Karissa M. Johnston, Stephanie Snow.

What is the DOI of this paper?

10.3390/curroncol33060308, permanently at https://doi.org/10.3390/curroncol33060308. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.